MacDonald N E, Halperin S A, Law B J, Forrest B, Danzig L E, Granoff D M
University of Ottawa, Ontario, Canada.
JAMA. 1998 Nov 18;280(19):1685-9. doi: 10.1001/jama.280.19.1685.
Meningococcal polysaccharide vaccines are not used routinely in infants and toddlers, the groups at highest risk of invasive disease, because of poor immunologic responses to the Neisseria meningitidis serogroup C polysaccharide in these age groups. Meningococcal C conjugate vaccines offer the prospect of circumventing this problem.
To assess the immunogenicity and the induction of immunologic memory in toddlers by meningococcal C conjugate vaccine.
A multicenter, randomized, observer-blinded controlled trial.
Urban and suburban family medicine or pediatric practices.
Two hundred eleven healthy toddlers aged 15 to 23 months.
Two injections at 2 months apart of meningococcal C conjugate (group 1, n = 69), plain meningococcal polysaccharide (group 2, n = 72), or hepatitis B virus vaccine (group 3, n = 70). All toddlers received a follow-up dose of plain meningococcal polysaccharide vaccine 12 months later.
IgG meningococcal C anticapsular antibody concentrations determined by enzyme-linked immunosorbent assay and complement-mediated bactericidal antibody.
In group 1, the magnitude of the IgG response to meningococcal C conjugate vaccine was more than 4-fold higher after dose 1 and more than 10-fold higher after dose 2 compared with meningococcal polysaccharide vaccine (group 2) (P<.001). Higher titers persisted in the meningococcal C conjugate group for at least 12 months (P<.001). Group 1, primed with meningococcal C conjugate, had 25-fold higher IgG responses to the meningococcal polysaccharide 1-year booster dose than the controls who had received hepatitis B virus vaccine initially and were given meningococcal polysaccharide vaccine 1 year later for the first time (P<.001). In contrast, group 2, primed with meningococcal polysaccharide, had a 2-fold lower response to the 1-year booster meningococcal polysaccharide dose than the hepatitis B virus control group (P = .006). Serum bactericidal responses paralleled the enzyme-linked immunosorbent assay responses.
Immunization of toddlers with meningococcal C conjugate vaccine induces high titers of anticapsular and bactericidal antibody. Furthermore, this vaccine induces immunologic memory to meningococcal C polysaccharide. In contrast, meningococcal polysaccharide vaccine is less immunogenic than the conjugate vaccine and also induces a hyporesponsive state that persists for at least 12 months.
由于婴幼儿对脑膜炎奈瑟菌C群多糖的免疫反应较差,而侵袭性疾病的高危人群正是婴幼儿,因此目前脑膜炎球菌多糖疫苗并不在婴幼儿中常规使用。脑膜炎球菌C结合疫苗有望解决这一问题。
评估脑膜炎球菌C结合疫苗对幼儿的免疫原性及免疫记忆的诱导作用。
一项多中心、随机、观察者盲法对照试验。
城市及郊区的家庭医学或儿科诊所。
211名年龄在15至23个月的健康幼儿。
两组幼儿在2个月的间隔内分别接种两次脑膜炎球菌C结合疫苗(第1组,n = 69)、普通脑膜炎球菌多糖疫苗(第2组,n = 72)或乙型肝炎病毒疫苗(第3组,n = 70)。所有幼儿在12个月后均接种一剂普通脑膜炎球菌多糖疫苗作为加强剂。
采用酶联免疫吸附测定法测定的IgG型脑膜炎球菌C抗荚膜抗体浓度及补体介导的杀菌抗体。
与脑膜炎球菌多糖疫苗组(第2组)相比,第1组在接种第1剂脑膜炎球菌C结合疫苗后IgG反应强度高出4倍多,接种第2剂后高出10倍多(P <.001)。脑膜炎球菌C结合疫苗组较高的抗体滴度至少持续了12个月(P <.001)。第1组在接种脑膜炎球菌C结合疫苗后,对1年后接种的脑膜炎球菌多糖加强剂的IgG反应比最初接种乙型肝炎病毒疫苗、1年后首次接种脑膜炎球菌多糖疫苗的对照组高出25倍(P <.001)。相比之下,第2组在接种脑膜炎球菌多糖疫苗后,对1年后接种的脑膜炎球菌多糖加强剂的反应比乙型肝炎病毒疫苗对照组低2倍(P =.006)。血清杀菌反应与酶联免疫吸附测定反应相似。
给幼儿接种脑膜炎球菌C结合疫苗可诱导产生高滴度的抗荚膜和杀菌抗体。此外,该疫苗还能诱导对脑膜炎球菌C多糖的免疫记忆。相比之下,脑膜炎球菌多糖疫苗的免疫原性低于结合疫苗,且还会诱导持续至少12个月的低反应状态。